Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 1.00 |
| ▸ | CA2 | P00918 | 13/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 2/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14726347 | 0.87 | CA1 (0.75) | CA1CA2CA12CA9 | |
| SCHEMBL11707345 | 0.80 | CA1 (0.67) | CA1CA2CA12CA9CES1 | |
| SCHEMBL5684413 | 0.78 | CA1 (0.64) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL3365092 | 0.78 | CA1 (0.64) | CA1CA2CA12CA9CES1 | |
| SCHEMBL6352180 | 0.78 | CA1 (0.64) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL8519790 | 0.76 | CA1 (1.00) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL1122831 | 0.76 | CA1 (0.61) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL479173 | 0.76 | KIF11 (0.88) | CA1CA2CA12CA9CES1 | |
| SCHEMBL15549491 | 0.76 | CA1 (0.61) | CA1CA2CA12CA9CES1 | |
| SCHEMBL3088460 | 0.76 | CA1 (0.61) | CA1CA2CA12CA9CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111100092-A | Method for direct amination of thioamide-oriented aromatic hydrocarbon carbon-hydrogen | 宁夏大学 | 2020-05-05 | — | — | CN | claimed |
| CN-113087687-A | Method for direct carbon-hydrogen alkynylation of thioamide-oriented aromatic hydrocarbon | 宁夏大学 | 2021-07-09 | — | — | CN | disclosed |
| CN-111100092-A | Method for direct amination of thioamide-oriented aromatic hydrocarbon carbon-hydrogen | 宁夏大学 | 2020-05-05 | — | — | CN | disclosed |
| CN-102816170-A | Novel macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE INC | 2012-12-12 | — | — | CN | disclosed |
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2305695-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305697-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305698-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1924594-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-1997037646-A1 | CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | CA1 4665/4885CA2 4474/4885CA12 4215/4885 |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | CA1 4665/4885CA2 4474/4885CA12 4215/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | CA1 4845/4885CA2 4605/4885CA12 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.